Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 17 | 2018 | 755 | 2.120 |
Why?
|
| HIV Infections | 17 | 2018 | 2586 | 1.140 |
Why?
|
| Endogenous Retroviruses | 5 | 2011 | 17 | 1.110 |
Why?
|
| Genotype | 8 | 2018 | 800 | 0.960 |
Why?
|
| RNA, Viral | 11 | 2011 | 321 | 0.810 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 91 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2007 | 229 | 0.530 |
Why?
|
| Viral Load | 11 | 2013 | 348 | 0.520 |
Why?
|
| Genetic Variation | 2 | 2015 | 430 | 0.480 |
Why?
|
| Cytomegalovirus | 2 | 2013 | 45 | 0.470 |
Why?
|
| Evolution, Molecular | 2 | 2015 | 307 | 0.440 |
Why?
|
| Seminal Vesicle Secretory Proteins | 1 | 2013 | 7 | 0.410 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 28 | 0.400 |
Why?
|
| Semen | 1 | 2013 | 57 | 0.400 |
Why?
|
| Drug Resistance, Viral | 5 | 2018 | 67 | 0.330 |
Why?
|
| Parkinsonian Disorders | 1 | 2010 | 42 | 0.320 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 91 | 0.320 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 652 | 0.300 |
Why?
|
| Needle Sharing | 1 | 2008 | 11 | 0.280 |
Why?
|
| Syringes | 1 | 2008 | 7 | 0.280 |
Why?
|
| Xylazine | 1 | 2008 | 4 | 0.280 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2008 | 32 | 0.280 |
Why?
|
| Rhodamine 123 | 1 | 2008 | 3 | 0.280 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 24 | 0.270 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 515 | 0.270 |
Why?
|
| HIV | 1 | 2008 | 100 | 0.270 |
Why?
|
| Humans | 32 | 2020 | 43102 | 0.260 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2008 | 129 | 0.260 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 182 | 0.250 |
Why?
|
| Virus Replication | 4 | 2013 | 318 | 0.240 |
Why?
|
| Parkinson Disease | 1 | 2007 | 210 | 0.230 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 386 | 0.220 |
Why?
|
| Gene Expression | 1 | 2007 | 701 | 0.200 |
Why?
|
| Hepatitis C | 3 | 2014 | 139 | 0.200 |
Why?
|
| Adult | 13 | 2020 | 13872 | 0.200 |
Why?
|
| Puerto Rico | 5 | 2018 | 1413 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2008 | 411 | 0.180 |
Why?
|
| Hepacivirus | 3 | 2010 | 74 | 0.180 |
Why?
|
| Saliva | 2 | 2020 | 119 | 0.170 |
Why?
|
| Child, Preschool | 2 | 2015 | 1546 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2018 | 247 | 0.150 |
Why?
|
| Executive Function | 1 | 2020 | 59 | 0.150 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 59 | 0.150 |
Why?
|
| Young Adult | 6 | 2020 | 5080 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2010 | 121 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2009 | 279 | 0.140 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2015 | 35 | 0.140 |
Why?
|
| Male | 14 | 2020 | 23409 | 0.140 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 1542 | 0.140 |
Why?
|
| Middle Aged | 9 | 2020 | 12222 | 0.140 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 1 | 0.130 |
Why?
|
| Child | 2 | 2015 | 3443 | 0.130 |
Why?
|
| Seizures | 1 | 2017 | 79 | 0.130 |
Why?
|
| Female | 12 | 2020 | 24698 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2017 | 131 | 0.120 |
Why?
|
| Dominican Republic | 1 | 2015 | 20 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 293 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2020 | 392 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2008 | 536 | 0.110 |
Why?
|
| Interleukins | 1 | 2014 | 40 | 0.110 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2005 | 57 | 0.110 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 486 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 226 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 609 | 0.110 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 17 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 758 | 0.110 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 64 | 0.100 |
Why?
|
| Adolescent | 3 | 2018 | 6081 | 0.100 |
Why?
|
| Virus Internalization | 1 | 2013 | 36 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 863 | 0.090 |
Why?
|
| Mutation | 4 | 2018 | 1177 | 0.090 |
Why?
|
| Aged | 4 | 2018 | 8214 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2010 | 311 | 0.090 |
Why?
|
| Viral Tropism | 1 | 2010 | 3 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2010 | 48 | 0.080 |
Why?
|
| Vaccines, Synthetic | 1 | 2010 | 80 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 863 | 0.080 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2009 | 5 | 0.070 |
Why?
|
| Genes, Immediate-Early | 1 | 2009 | 10 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 75 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2010 | 306 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2009 | 74 | 0.070 |
Why?
|
| Substance Abuse Detection | 1 | 2008 | 31 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2009 | 113 | 0.070 |
Why?
|
| Saquinavir | 1 | 2008 | 3 | 0.070 |
Why?
|
| Verapamil | 1 | 2008 | 7 | 0.070 |
Why?
|
| Simian immunodeficiency virus | 2 | 2005 | 60 | 0.070 |
Why?
|
| Ritonavir | 1 | 2008 | 15 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 83 | 0.070 |
Why?
|
| Vagina | 2 | 2005 | 89 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 55 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 60 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 611 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 220 | 0.060 |
Why?
|
| Ionophores | 1 | 2007 | 11 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2009 | 1621 | 0.060 |
Why?
|
| Ionomycin | 1 | 2007 | 11 | 0.060 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2006 | 3 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 223 | 0.060 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2006 | 3 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 102 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 43 | 0.060 |
Why?
|
| Immunization Schedule | 1 | 2006 | 9 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2007 | 17 | 0.060 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 41 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2008 | 359 | 0.060 |
Why?
|
| Diamines | 1 | 2006 | 8 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2006 | 26 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2006 | 36 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 306 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2006 | 107 | 0.060 |
Why?
|
| Kinetics | 1 | 2007 | 695 | 0.060 |
Why?
|
| Fluorescence | 1 | 2006 | 118 | 0.060 |
Why?
|
| Retroviruses, Simian | 1 | 2005 | 3 | 0.060 |
Why?
|
| Quinolines | 1 | 2006 | 78 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 314 | 0.060 |
Why?
|
| HIV Seropositivity | 1 | 2007 | 196 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2008 | 457 | 0.060 |
Why?
|
| Mice | 2 | 2013 | 6644 | 0.050 |
Why?
|
| Morphine Dependence | 1 | 2004 | 23 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 575 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 201 | 0.050 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 10 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 29 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 983 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 76 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 91 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1063 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2007 | 1604 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 1081 | 0.050 |
Why?
|
| Animals | 4 | 2013 | 16992 | 0.040 |
Why?
|
| Alcoholism | 1 | 2005 | 305 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2853 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 830 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 41 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2676 | 0.040 |
Why?
|
| Phylogeny | 3 | 2011 | 769 | 0.040 |
Why?
|
| Alcohol-Related Disorders | 1 | 2020 | 63 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 54 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 203 | 0.030 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2017 | 3 | 0.030 |
Why?
|
| Japan | 1 | 2017 | 348 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 455 | 0.030 |
Why?
|
| Genes, pol | 2 | 2005 | 15 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 21 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 23 | 0.030 |
Why?
|
| Interferons | 1 | 2014 | 40 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 678 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2005 | 139 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 206 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 108 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1078 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 352 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1612 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1070 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 518 | 0.020 |
Why?
|
| Jamaica | 1 | 2013 | 11 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2014 | 195 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 437 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1180 | 0.020 |
Why?
|
| Reverse Transcription | 1 | 2011 | 23 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 95 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2011 | 119 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 734 | 0.020 |
Why?
|
| Antigenic Variation | 1 | 2010 | 8 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2010 | 17 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 44 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 2544 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2010 | 53 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 9 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 21 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 94 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 114 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 71 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 31 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2009 | 41 | 0.020 |
Why?
|
| RNA Precursors | 1 | 2009 | 28 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 173 | 0.020 |
Why?
|
| India | 1 | 2009 | 108 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 694 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3994 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 189 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 440 | 0.020 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2006 | 12 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 526 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 74 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 333 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2005 | 29 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 1082 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 1410 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 20 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 37 | 0.010 |
Why?
|
| Narcotics | 1 | 2004 | 29 | 0.010 |
Why?
|
| Candidiasis, Oral | 1 | 2004 | 24 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 267 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 44 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2004 | 61 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 3156 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 184 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 272 | 0.010 |
Why?
|
| Morphine | 1 | 2004 | 69 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 135 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 13 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 157 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 62 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 40 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1175 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 458 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1857 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 372 | 0.010 |
Why?
|